Panelists discuss how; the patient case presents a 47-Year-Old Woman with EGFR-mutated Advanced/Metastatic NSCLC. The patient ...

AceLink is advancing a small-molecule treatment option for Fabry disease, which could provide a more convenient alternative ...

This study challenges the common practice of using ACE inhibitors as the first-choice treatment for high blood pressure. The ...

Though highly effective, medications for the prevention of chronic kidney disease progression are under-utilized, emphasizing the need for better use of prognostic tools.